Moors & Cabot Inc. acquired a new stake in shares of Mylan N.V. (NASDAQ:MYL) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 11,075 shares of the company’s stock, valued at approximately $429,000.
Several other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in Mylan N.V. by 4.5% during the 2nd quarter. BlackRock Inc. now owns 40,574,158 shares of the company’s stock valued at $1,575,089,000 after acquiring an additional 1,751,515 shares during the period. Vanguard Group Inc. boosted its holdings in Mylan N.V. by 12.0% during the 2nd quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock valued at $1,276,432,000 after acquiring an additional 3,531,974 shares during the period. State Street Corp boosted its holdings in Mylan N.V. by 1.6% during the 2nd quarter. State Street Corp now owns 20,498,541 shares of the company’s stock valued at $795,751,000 after acquiring an additional 321,977 shares during the period. Pzena Investment Management LLC boosted its holdings in Mylan N.V. by 69.9% during the 2nd quarter. Pzena Investment Management LLC now owns 12,339,687 shares of the company’s stock valued at $479,027,000 after acquiring an additional 5,077,371 shares during the period. Finally, FIL Ltd lifted its holdings in Mylan N.V. by 1.9% in the 2nd quarter. FIL Ltd now owns 5,029,770 shares of the company’s stock worth $195,255,000 after buying an additional 95,505 shares during the period. Hedge funds and other institutional investors own 71.97% of the company’s stock.
Mylan N.V. (NASDAQ:MYL) traded up 0.05% on Wednesday, reaching $38.47. The company had a trading volume of 577,227 shares. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87. The stock’s 50-day moving average is $32.53 and its 200-day moving average is $36.33. The company has a market capitalization of $20.63 billion, a P/E ratio of 31.10 and a beta of 1.30.
Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). The business had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.16 earnings per share. Equities research analysts forecast that Mylan N.V. will post $4.58 EPS for the current fiscal year.
Several equities research analysts have weighed in on the company. Cowen and Company reiterated a “hold” rating and issued a $30.00 price objective (down previously from $43.00) on shares of Mylan N.V. in a report on Wednesday, August 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $32.00 price objective (down previously from $33.00) on shares of Mylan N.V. in a report on Thursday, August 10th. Citigroup Inc. upgraded Mylan N.V. from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $36.00 to $42.00 in a report on Wednesday, August 16th. Wells Fargo & Company set a $32.00 price objective on Mylan N.V. and gave the stock a “hold” rating in a report on Wednesday, October 4th. Finally, Zacks Investment Research upgraded Mylan N.V. from a “strong sell” rating to a “hold” rating and set a $43.00 price objective for the company in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $41.21.
Mylan N.V. Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.